<DOC>
	<DOCNO>NCT00070200</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , topotecan cyclophosphamide , use different way stop tumor cell divide stop grow die . Combining chemotherapy autologous stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : This phase I trial study side effect induction chemotherapy use cyclophosphamide topotecan treating patient undergo surgery autologous stem cell transplantation follow radiation therapy newly diagnose progressive neuroblastoma .</brief_summary>
	<brief_title>Induction Chemotherapy Using Cyclophosphamide Topotecan Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation Newly Diagnosed Progressive Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity feasibility add cyclophosphamide topotecan induction therapy patient newly diagnose progressive high-risk neuroblastoma undergo autologous peripheral blood stem cell ( PBSC ) transplantation . - Determine feasibility PBSC mobilization vivo PBSC tumor purge patient treatment regimen . Secondary - Determine tumor response rate patient treat regimen . - Determine pharmacokinetics regimen patient . - Determine whether topotecan affect cyclophosphamide pharmacokinetics patient . - Correlate host DNA toxicity cyclophosphamide topotecan pharmacokinetics patient treat regimen . - Determine toxicity patient treated regimen . OUTLINE : This pilot , multicenter study . Patients stratify accord diagnosis ( newly diagnose v initially stage 1 , 2 , 4S progress stage 4 without interval chemotherapy ) . - Induction therapy : Patients receive 6 course induction therapy . - Courses 1 2 : Patients receive cyclophosphamide IV 30 minute topotecan IV 30 minute day 1-5 filgrastim ( G-CSF ) subcutaneously ( SC ) IV begin day 6 continue blood count recover . - Course 3 : Patients receive etoposide IV 2 hour day 1-3 , cisplatin IV 1 hour day 1-4 , G-CSF SC IV begin day 5 continue blood count recover . - Course 4 : Patients receive cyclophosphamide IV 6 hour day 1 doxorubicin IV vincristine IV continuously 24 hour day 1-3 . Patients also receive G-CSF SC IV begin day 4 continue blood count recover . - Course 5 : Patients receive etoposide , cisplatin , G-CSF course 3 . - Course 6 : Patients receive cyclophosphamide , doxorubicin , vincristine , G-CSF course 4 . Treatment repeat every 21 day total 6 course absence disease progression unacceptable toxicity . - Consolidation therapy : Within 4-6 week complete induction therapy , patient receive melphalan IV day -7 -5 etoposide IV carboplatin IV continuously 24 hour day -7 -4 . - Stem cell transplantation : Peripheral blood stem cell collect course 2 induction therapy infuse day 0 . Patients receive G-CSF IV begin day 0 continue blood count recover . - Surgery : After course 5 induction therapy , patient undergo surgery . - Radiotherapy : Beginning 28-42 day transplantation , patient receive 12 fraction local radiotherapy area residual soft tissue disease primary tumor site , even completely resect . - Maintenance therapy : Beginning 66 day transplantation , patient receive oral isotretinoin twice daily day 1-14 . Treatment repeat every 28 day total 6 course . Patients follow every 3 month 1 year , every 6 month 4 year , annually thereafter . PROJECTED ACCRUAL : A total 10-29 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm neuroblastoma ganglioneuroblastoma meeting 1 follow stag criterion : Newly diagnose disease , least 1 year age , meet criteria 1 following : International Neuroblastoma Staging System ( INSS ) stage 2a/2b MYCN amplification ( great 10 ) AND unfavorable pathology INSS stage 3 MYCN amplification OR unfavorable pathology Newly diagnose INSS stage 4 disease meeting criterion 1 follow : Over 18 month age Age 12 18 month unfavorable biologic feature ( MYCN amplification , unfavorable pathology , and/or DNA index=1 ) biologic feature indeterminant , unsatisfactory , unknown No INSS stage 4 disease age 12 18 month 3 favorable biologic feature ( i.e. , nonamplified MYCN , favorable pathology , DNA index great 1 ) Newly diagnose INSS stage 3 , 4 , 4S disease AND 1 year age MYCN amplification At least 1 year age initially diagnose INSS stage 1 , 2 , 4S disease progress stage 4 without interval chemotherapy Must enrol COGANBL00B1 initial diagnosis PATIENT CHARACTERISTICS : Age 30 initial diagnosis Performance status Not specify Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,000/mm^3* Platelet count least 100,000/mm^3* ( transfusion independent ) Hemoglobin least 10.0 g/dL* ( red blood cell transfusion allow ) NOTE : *Granulocytopenia , anemia , and/or thrombocytopenia allow patient tumor metastatic bone marrow Hepatic Bilirubin great 1.5 mg/dL ALT le 300 IU/L Renal Creatinine great 1.5 mg/dL Creatinine clearance radioisotope glomerular filtration rate least 60 mL/min Cardiovascular ECG normal Shortening fraction least 27 % echocardiogram OR Ejection fraction least 50 % MUGA Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No 1 prior chemotherapy course low intermediaterisk neuroblastoma study ( COGP9641 , COGA3961 ) prior determination MYCN amplification Shimada histology Endocrine therapy Not specify Radiotherapy Prior localize emergency radiotherapy sit lifethreatening functionthreatening disease allow Surgery Not specify Other No prior systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
</DOC>